Hottest Stocks
(Over $10)
Hottest Stocks
($2-$10)
Biggest Losers
(Over $10)
Biggest Losers
($2-$10)
Hottest
Industries
Hottest
Sectors
EPS / Sales
Surprises
 
Enter Ticker Symbol:   Ticker Lookup
 

Enter any portion of the company’s name to find its corresponding ticker symbol:
Search for :   

Zacks Company Profile for ARAVIVE, INC (ARAV : NSDQ)
 
 • Company Description   
Aravive Inc. is a biotechnology company. It develops therapeutic proteins for the treatment of metabolic diseases and endocrine disorders. Aravive Inc. is based in TX, United States.

Number of Employees: 23

 
 • Price / Volume Information   
Yesterday's Closing Price: $1.07 Daily Weekly Monthly
20 Day Moving Average: 74,328 shares
Shares Outstanding: 28.83 (millions)
Market Capitalization: $30.84 (millions)
Beta: 2.57
52 Week High: $6.94
52 Week Low: $1.02
Short Interest Ratio:
  % Price Change % Price Change Relative to S&P 500
4 Week -34.76% -28.56%
12 Week -50.69% -44.58%
Year To Date -51.14% -40.31%
 
 • Address & Contact Information
Street Address Phone / Fax Email Address Web URL
River Oaks Tower 3730 Kirby Drive Suite 1200
-
Houston,TX 77098
USA
ph: 936-355-1910
fax: -
lheagle@w2ogroup.com https://aravive.com
 
 • General Corporate Information   
Officers
Gail McIntyre - President; Chief Executive Officer and Director
Fredric N. Eshelman - Executive Chairman of the Board of Directors
Leonard Scott Dove - Chief Operating Officer
Vinay Shah - Chief Financial Officer
Sigurd C. Kirk - Director

Peer Information
ARAVIVE, INC (CORR.)
ARAVIVE, INC (RSPI)
ARAVIVE, INC (CGXP)
ARAVIVE, INC (BGEN)
ARAVIVE, INC (GTBP)
ARAVIVE, INC (RGRX)
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED-BIOMED/GENE
Sector: Medical
CUSIP: 03890D108
SIC: 2834
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: 03/01/22
Next Expected EPS Date: 08/04/22
Share - Related Items
Shares Outstanding: 28.83
Most Recent Split Date: 10.00 (0.17:1)
Beta: 2.57
Market Capitalization: $30.84 (millions)
 
 
 • EPS Information     • Dividend Information
Analyst Coverage: No Dividend Yield: 0.00%
Current Fiscal Quarter EPS Consensus Estimate: $-0.58 Indicated Annual Dividend: $0.00
Current Fiscal Year EPS Consensus Estimate: $-2.35 Payout Ratio:
Number of Estimates in the Fiscal Year Consensus: 4.00 Change In Payout Ratio:
Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00
Next EPS Report Date: 08/04/22  
 

 • Fundamental Ratios
P/E
Current FY Estimate: -
Trailing 12 Months: -
PEG Ratio: -
Price Ratios
Price/Book: 0.66
Price/Cash Flow: -
Price / Sales: 3.73
EPS Growth
vs. Year Ago Period: -40.91%
vs. Previous Quarter: 0.00%
Sales Growth
vs. Year Ago Period: 326.56%
vs. Previous Quarter: 10.86%
ROE
03/31/22 - -88.49
12/31/21 - -68.29
09/30/21 - -51.44
ROA
03/31/22 - -58.22
12/31/21 - -49.39
09/30/21 - -38.16
Current Ratio
03/31/22 - 3.49
12/31/21 - 3.50
09/30/21 - 5.04
Quick Ratio
03/31/22 - 3.49
12/31/21 - 3.50
09/30/21 - 5.04
Operating Margin
03/31/22 - -533.99
12/31/21 - -526.08
09/30/21 - -249.06
Net Margin
03/31/22 - -533.99
12/31/21 - -526.08
09/30/21 - -249.06
Pre-Tax Margin
03/31/22 - -533.99
12/31/21 - -526.08
09/30/21 - -249.06
Book Value
03/31/22 - 1.61
12/31/21 - 2.01
09/30/21 - 2.59
Inventory Turnover
03/31/22 - -
12/31/21 - -
09/30/21 - -
Debt-to-Equity
03/31/22 - 0.00
12/31/21 - 0.00
09/30/21 - 0.00
Debt-to-Capital
03/31/22 - 0.00
12/31/21 - 0.00
09/30/21 - 0.00
 

Powered by Zacks Investment Research ©